HIV therapeutics in 2026. (PubMed, Clin Microbiol Rev) - Oct 1, 2026 - "Dolutegravir and bictegravir are now the anchors of most first-line therapies worldwide, and two-drug and nucleoside reverse transcriptase inhibitor (NRTI)-sparing strategies have emerged, allowing for simplification of treatment of patients who had been previously on complex regimens...For people with multidrug-resistant HIV, new agents including fostemsavir, ibalizumab, and lenacapavir have made virologic suppression achievable in virtually all heavily treatment-experienced patients...These advances, however, come with potential challenges, including emergent resistance to long-acting agents, metabolic consequences of lifelong therapy in an aging population, persistent inequities in global access to newer agents, and often insufficient safety data in pregnancy and breastfeeding. This review provides a clinical assessment of the current antiretroviral options, from legacy agents to investigational therapies, with attention to the resistance, implementation, and..."
Journal • Review • Human Immunodeficiency Virus • Infectious Disease
|
|
Carlos S Saldana; Danilo Bacic Lima; Joseph N Cherabie; Yijia Li
|